CHRISTOPHER J. COUGHLIN - 03 Jan 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
Director
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Jan 2023
Net transactions value
+$107,944
Form type
4
Filing time
05 Jan 2023, 15:45:31 UTC
Previous filing
04 Jan 2023
Next filing
04 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Award $35,442 +321 $110.41 321 03 Jan 2023 Common Stock 321 $193.19 Direct F1, F2
transaction KRTX Option (right to buy) Award $45,002 +407 $110.57 407 03 Jan 2023 Common Stock 407 $193.19 Direct F1, F2
transaction KRTX Option (right to buy) Award $7,500 +67 $111.94 67 03 Jan 2023 Common Stock 67 $193.19 Direct F1, F2
transaction KRTX Option (right to buy) Award $20,000 +181 $110.50 181 03 Jan 2023 Common Stock 181 $193.19 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees for board services in 2023.
F2 This option vests as to 25% of the shares underlying the option award on each three month anniversary following the vesting commencement date of January 3, 2023.